AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma

5 years ago

by David Miller

950 Views

Written by David Miller

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!